Saturday , October 16 2021

Jubilant Life Science’s arm enters into SPA to acquire stake in Inipharm

Jubilant Life Science’s wholly-owned subsidiary company — Drug Discovery and Development Solutions, Singapore (DDDSL) — has entered into Stock Purchase Agreement (SPA) on November 29, 2018 for acquiring 534,194 shares of Common Stock of Inipharm Inc., USA. The cost of acquisition or the price at which the shares are acquired is $534.20.

Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.

Please share this news
<div id="taboola-below-article-thumbnails"></div>
<script type="text/javascript">
  window._taboola = window._taboola || [];
    mode: 'thumbnails-a',
    container: 'taboola-below-article-thumbnails',
    placement: 'Below Article Thumbnails',
    target_type: 'mix'